Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBiotics, which designs and develops peptide antifungal and antibacterial therapeutics, has signed a collaboration agreement with Isogenica, to fast-track the development of its anti-infective peptide technology platform.
Subscribe to our email newsletter
Under the contract, NovaBiotics is expected to work on peptide selection and maturation with Isogenica to expand its product portfolio.
NovaBiotics founder Deborah O’Neil said that Isogenica’s experts in the field of peptide engineering and their CIS–Display technology is ideal for screening the companys library of anti-infective peptides as efficiently as possible and enabling NovaBiotics to fast-track the development of its product pipeline.
Isogenica CEO Kevin Matthews said that following on from the successful antimicrobial project with Dstl, they are delighted that NovaBiotics has chosen Isogenica as their partner for these two projects.
“As a company we are focused on servicing the protein engineering needs of the pharmaceutical and biotech industries and as a result of such partnerships we are discovering active lead candidates for drug development,” Matthews said.